Kimberly-Clark Closes $48.7 Billion Kenvue Deal, Enters Beauty

Kimberly-Clark has completed its US$48.7 billion acquisition of Kenvue, putting Neutrogena, Aveeno, OGX and Listerine under the same corporate roof as Kleenex, Huggies, Andrex and Kotex. The deal, announced in a company statement, marks the 154-year-old company's first major push into the beauty category.

For dermatology-adjacent skincare, the consolidation matters. Neutrogena and Aveeno — two of the most recommended mass-market dermocosmetic lines in U.S. pharmacy channels — now sit inside a personal care giant rather than a standalone consumer health spin-off. Kimberly-Clark says the combined business can "provide preferred solutions through every stage of life."

What does the deal change?

Kenvue was spun off from Johnson & Johnson in 2023. Beyond beauty, it brought a health care stable: Tylenol, Benadryl and Nicorette all move to Kimberly-Clark's ownership under the agreement.

The company claims it is now positioned to capture growing demand for "science-backed, high-quality and high-performance solutions across everyday needs." That claim is a manufacturer statement, not trial data — but it signals where the merged portfolio's marketing muscle will point: efficacy-led positioning for consumer skincare and wellness.

The new structure organizes the business into four segments:

• North America
• Asia-Pacific-focused markets, including Greater China, Australia/New Zealand, South Korea and Indonesia
• Europe, the Middle East and Africa (EMEA)
• Enterprise markets, covering Latin America (including Brazil), India, Southeast Asia markets and Japan

What did the CEO say?

Mike Hsu, Chairman and CEO of Kimberly-Clark, framed the close as a milestone. "Today marks a defining moment in Kimberly-Clark's 154-year history as we welcome Kenvue and hit the ground running as one company," Hsu said. "I am deeply grateful to our Kimberly-Clark and Kenvue teams around the world for enabling this next step."

He pointed to a shared commercial DNA. "We share a rich heritage: pioneering entire categories and forming deep, lifelong bonds with consumers around the world as we help generations of people take care of themselves and their loved ones, every day."

Hsu also gestured at demand tailwinds. "Now, at a moment when the need for better care is undeniable and growing, we have an urgent opportunity to be there for more people, in more places and across evolving unmet needs."

On execution, he was blunt about pace. "Our focus now is to move with speed and purpose to unlock the full potential of this combination. I am confident that our shared commitment to care and strong execution will enable us to deliver generational value for consumers, customers and shareholders."

Why did Kenvue sell?

The takeover didn't come from a position of strength. Kenvue opened a strategic review of its business in July, against a backdrop of falling sales and job cuts. That review set the stage for the transaction now completed.

The takeaway in plain words: a $48.7 billion check has moved two of pharmacy skincare's biggest names into a household-goods empire betting that "science-backed" everyday care is where consumer dollars are heading — and integration, not intention, will decide whether that bet pays off.